Annexon FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Annexon in a research note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($1.47) for the year, down from their previous forecast of ($0.99). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Several other brokerages have also commented on ANNX. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has an average rating of “Buy” and a consensus price target of $15.80.

Annexon Price Performance

Shares of NASDAQ ANNX opened at $2.76 on Thursday. The stock has a market capitalization of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14. The firm’s 50 day simple moving average is $3.85 and its 200-day simple moving average is $5.38. Annexon has a 12 month low of $2.30 and a 12 month high of $8.40.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05).

Institutional Investors Weigh In On Annexon

Several institutional investors have recently modified their holdings of the company. Parkman Healthcare Partners LLC raised its position in shares of Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after acquiring an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Annexon by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock valued at $945,000 after purchasing an additional 2,450 shares during the last quarter. GSA Capital Partners LLP raised its holdings in Annexon by 10.7% during the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after purchasing an additional 3,355 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after buying an additional 4,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Annexon by 6.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock valued at $325,000 after buying an additional 4,092 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.